Most hepatocellular carcinomas are diagnosed at intermediate or advanced stages, and only a minority of patients with tumors larger than 3 cm benefit from curative treatments. Radiofrequency thermal ablation (RFA) has been used effectively to treat small tumors, and some studies suggest that transarterial chemoembolization (TACE) improves survival in patients with hepatocellular carcinoma. To assess whether treating patients with TACE and RFA may offer a survival benefit, Cheng and colleagues Article randomly assigned 291 patients with hepatocellular carcinomas larger than 3 cm to treatment with TACE-RFA, TACE alone, or RFA alone. During a median 28.5 months of follow-up, median survival times were 37 months in the TACE-RFA group, 24 months in the TACE-alone group, and 22 months in the RFA-alone group. In an editorial, Zhu and Abou-Alfa Article discuss expanding treatment options for hepatocellular carcinoma.